Dezocine

Dezocine
Clinical data
Trade namesDalgan
Other namesWY-16,225; WY-16225
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Intravenous infusion, intramuscular injection[1]
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismHepatic
Elimination half-life2.2 hours
Identifiers
  • (5R,11S,13R)-13-Amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H23NO
Molar mass245.366 g·mol−1
3D model (JSmol)
  • Oc1ccc2c(c1)[C@@]3(C)CCCCC[C@@H](C2)[C@H]3N
  • InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1 checkY
  • Key:VTMVHDZWSFQSQP-VBNZEHGJSA-N checkY
  (verify)

Dezocine, sold under the brand name Dalgan, is an atypical opioid analgesic which is used in the treatment of pain.[1][2] It is used by intravenous infusion and intramuscular injection.[1][2]

Dezocine is an opioid receptor modulator, acting as a partial agonist of the μ- and κ-opioid receptors.[2] It is a biased agonist of the μ-opioid receptor.[3][4] The drug has a similar profile of effects to related opioids acting at the μ-opioid receptor, including analgesia and euphoria.[2][5] Unlike other opioids acting at the κ-opioid receptor however, dezocine does not produce side effects such as dysphoria or hallucinations at any therapeutically used dose.[6]

Dezocine was first synthesized in 1970.[7] It was introduced for medical use in the United States in 1986 but was not marketed in other countries.[2][8] Dezocine was discontinued in the United States in 2011 with no official reason given.[2] However, it has become one of the most widely used analgesics in China.[2] In light of the opioid epidemic, dezocine has seen a resurgence in use and interest.[2]

  1. ^ a b c O'Brien JJ, Benfield P (August 1989). "Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy". Drugs. 38 (2): 226–48. doi:10.2165/00003495-198938020-00005. PMID 2670517. S2CID 195697572.
  2. ^ a b c d e f g h Childers WE, Abou-Gharbia MA (June 2021). ""I'll Be Back": The Resurrection of Dezocine". ACS Med Chem Lett. 12 (6): 961–968. doi:10.1021/acsmedchemlett.1c00233. PMC 8201756. PMID 34141081.
  3. ^ Cite error: The named reference BarrSchmidtThakrar2024 was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference GrothusenLinXi2022 was invoked but never defined (see the help page).
  5. ^ Zacny JP, Lichtor JL, de Wit H (April 1992). "Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers". Anesthesia and Analgesia. 74 (4): 523–30. doi:10.1213/00000539-199204000-00010. PMID 1348168. S2CID 34394471.
  6. ^ Westmoreland C (August 1991). "Opioid agonist-antagonists". Current Opinion in Anesthesiology. 4 (4): 556–562. doi:10.1097/00001503-199108000-00017.
  7. ^ "Espacenet". Espacenet Patent Search.
  8. ^ Cite error: The named reference SwissPharmaceuticalSociety2000 was invoked but never defined (see the help page).